Literature DB >> 7960600

Different biological effects of the two protein kinase C activators bryostatin-1 and TPA on human carcinoma cell lines.

K G Steube1, D Grunicke, H G Drexler.   

Abstract

Bryostatin 1 (Bryo) is a naturally occurring macrocyclic lactone with antineoplastic activity. Like the phorbol ester 12-O-tetradecanoyl-phorbol 13-acetate (TPA) it directly activates the calcium- and phospholipid-dependent protein kinase C (PKC), thus generating a number of different cellular responses. We investigated the effects of Bryo and TPA on DNA synthesis, proliferation, viability and c-myc protooncogene expression of the human carcinoma cell lines COLO-320, MEL-HO, and KB-3-1. TPA inhibited [3H]-thymidine incorporation in all three cell lines in a dose-dependent manner, whereas Bryo only inhibited the DNA synthesis in MEL-HO, but not in KB-3-1 and COLO-320 cells. Within the concentration ranges used, TPA and Bryo were found to have a low toxicity. Counting of the cells confirmed the observed inhibition of cell proliferation. However, the enzymatic conversion of MTT, applied as a colorimetric proliferation assay, was not significantly affected by both biomodulators. Time-course experiments revealed a rapid onset of the inhibitory effect on DNA synthesis. Bryo was further able to antagonize the TPA-mediated effects on proliferation suggesting an (at least partially) different mode of action of these PKC activators. Incubation of MEL-HO and COLO-320 cells with either of the two biomodulators resulted in a rapid and strong increase of c-myc mRNA. The present study emphasizes Bryo as an interesting, natural substance for the study of PKC-mediated biological effects.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7960600     DOI: 10.1007/BF00873230

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  41 in total

Review 1.  myc function and regulation.

Authors:  K B Marcu; S A Bossone; A J Patel
Journal:  Annu Rev Biochem       Date:  1992       Impact factor: 23.643

Review 2.  The bryostatins.

Authors:  G R Pettit
Journal:  Fortschr Chem Org Naturst       Date:  1991

3.  Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity.

Authors:  R L Hornung; J W Pearson; M Beckwith; D L Longo
Journal:  Cancer Res       Date:  1992-01-01       Impact factor: 12.701

Review 4.  The protein kinase C family: heterogeneity and its implications.

Authors:  U Kikkawa; A Kishimoto; Y Nishizuka
Journal:  Annu Rev Biochem       Date:  1989       Impact factor: 23.643

5.  Cell lines from human colon carcinoma with unusual cell products, double minutes, and homogeneously staining regions.

Authors:  L A Quinn; G E Moore; R T Morgan; L K Woods
Journal:  Cancer Res       Date:  1979-12       Impact factor: 12.701

6.  Selective translocation of beta II-protein kinase C to the nucleus of human promyelocytic (HL60) leukemia cells.

Authors:  B A Hocevar; A P Fields
Journal:  J Biol Chem       Date:  1991-01-05       Impact factor: 5.157

7.  Inhibition by bryostatin 1 of the phorbol ester-induced blockage of differentiation in hexamethylene bisacetamide-treated Friend erythroleukemia cells.

Authors:  M L Dell'Aquila; H T Nguyen; C L Herald; G R Pettit; P M Blumberg
Journal:  Cancer Res       Date:  1987-11-15       Impact factor: 12.701

8.  Effects of bryostatins 1 and 2 on morphological and functional differentiation of SH-SY5Y human neuroblastoma cells.

Authors:  A M Jalava; J Heikkilä; G Akerlind; G R Pettit; K E Akerman
Journal:  Cancer Res       Date:  1990-06-01       Impact factor: 12.701

9.  Successful treatment of murine melanoma with bryostatin 1.

Authors:  L M Schuchter; A H Esa; S May; M K Laulis; G R Pettit; A D Hess
Journal:  Cancer Res       Date:  1991-01-15       Impact factor: 12.701

10.  Surface antigens of human melanoma cells defined by monoclonal antibodies. I. Biochemical characterization of two antigens found on cell lines and fresh tumors of diverse tissue origin.

Authors:  J P Johnson; M Demmer-Dieckmann; T Meo; M R Hadam; G Riethmüller
Journal:  Eur J Immunol       Date:  1981-10       Impact factor: 5.532

View more
  1 in total

1.  "Picolog," a synthetically-available bryostatin analog, inhibits growth of MYC-induced lymphoma in vivo.

Authors:  Brian A DeChristopher; Alice C Fan; Dean W Felsher; Paul A Wender
Journal:  Oncotarget       Date:  2012-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.